

HemoSense®

**CoagCare**®  
FROM ZYCARE

**For Further Information Contact:**

**HemoSense, Inc.**

Gordon Sangster, VP Finance & CFO  
[gsangster@hemosense.com](mailto:gsangster@hemosense.com)  
(408) 240-3794

**Lippert/Heilshorn & Associates**

Don Markley or Brandi Floberg  
[bfloberg@lhai.com](mailto:bfloberg@lhai.com)  
(310) 691-7100

**ZyCare, Inc.**

Sandra Cummings, President  
[scummings@zycare.com](mailto:scummings@zycare.com)  
919-338-2218

**HemoSense and ZyCare Partner with Pima Heart to Utilize  
Web-Based Warfarin Patient Management System for INRatio**

**SAN JOSE, Calif. and CHAPEL HILL, N.C., May 4, 2007 – HemoSense, Inc.**

**(AMEX:HEM)** HemoSense, Inc. and ZyCare, Inc. today announced that Pima Heart, a cardiology practice that provides medical and surgical services in southern Arizona, will use ZyCare's CoagCare® software management system to remotely manage Pima Heart patients who wish to use HemoSense's portable INRatio® PT/INR monitoring system for self-testing. CoagCare will also be used as the point-of-care anticoagulation management software in all seven Pima Heart locations.

After performing a PT/INR test with the INRatio system, patients use a standard Internet browser to input INR test results and information about symptoms and illness into the CoagCare system. CoagCare then provides automated, patient specific warfarin dosage adjustments based on physician-prescribed algorithms. Test results are immediately available to healthcare providers, and patients who report out of range INR values, hemorrhagic, or thromboembolic symptoms, are prioritized for physician review. CoagCare is the only U.S. Food and Drug Administration (FDA) cleared, HIPAA compatible remote INR test reporting and dosage management system for patients on oral anticoagulant therapy.

"Pima Heart currently utilizes our INRatio system in its anticoagulation clinics and the expansion of this relationship is a testament to the technical capabilities and versatility of our INRatio product, as well as the strength of ZyCare's Web-based management tools," said Timothy Still, executive VP and chief commercial officer of HemoSense.

"Of the millions of people taking warfarin there is a tremendous opportunity to improve their care and lives through more frequent testing, better monitoring and education," said Ted Ranney, Pima Heart chief executive officer. "We believe that the promotion of home-testing and offering additional management tools assist in affording patients this opportunity. We are excited to offer this new service to our patients."

Pima Heart currently manages more than 1,000 patients taking warfarin. By using the INRatio and instituting the CoagCare system, Pima Heart expects to be able to reduce

the number of patient visits to its clinics, while effectively managing patient self-testers, so that it can focus on the critical patients who need the most attention.

“We are delighted with the expansion of our relationship with HemoSense, and our new relationship with a patient focused organization such as Pima Heart, in order to bring the benefits of CoagCare and 'supervised self-management'<sup>™</sup> to the patients of southern Arizona,” said Sandra Cummings, president of ZyCare.

#### **About Pima Heart**

Pima Heart, of Tucson, Ariz., was founded in 1981 and today is the largest cardiovascular practice in southern Arizona, with 25 cardiologists, eight nurse practitioners and a highly trained support staff serving multiple communities throughout southern Arizona. Pima Heart is a team dedicated to providing comprehensive cardiac care, with a commitment to reducing the incidence, prevalence and mortality of cardiovascular disease while providing quality care and personal service.

#### **About ZyCare**

ZyCare develops medical information technology solutions that increase productivity for healthcare professionals in the management of chronic diseases while simultaneously improving quality of patient care and reducing costs. ZyCare utilizes innovative web-based “direct-to-patient expert systems”<sup>™</sup> to automate much of the routine decision making involved in managing patients remotely. ZyCare's solutions directly involve patients in the information gathering that drives automated treatment recommendations, while giving physicians a vehicle to closely monitor their patient's progress without time consuming telephone calls and faxes. This approach allows the healthcare system to cost-effectively take advantage of new home monitoring devices for chronic conditions, while giving patients more control over their own condition. ZyCare's technology is protected by patents issued in the United States, Canada, Europe and Australia. For more information, visit [www.coagcare.com](http://www.coagcare.com).

#### **About HemoSense**

HemoSense is a point-of-care diagnostic healthcare company that develops, manufactures and markets easy-to-use, handheld blood coagulation systems for monitoring patients taking warfarin. The HemoSense INRatio(R) system, used by healthcare professionals and patients themselves, consists of a small monitor and disposable test strips. It provides accurate and convenient measurement of blood clotting time, or PT/INR values. Routine measurements of PT/INR are necessary for the safe and effective management of the patient's warfarin dosing. INRatio is sold in the United States and internationally. For more information, visit [www.hemosense.com](http://www.hemosense.com).

*HemoSense® and INRatio® are registered trademarks of HemoSense, Inc. CoagCare® and ZyCare® are registered trademarks of ZyCare, Inc. "Supervised Self-Management" and "Direct-to-Patient Expert Systems" are trademarks of ZyCare, Inc.*